D. Western Therapeutics Institute, Inc. (TYO:4576)

Market Cap	5.21B +0.5%
Revenue (ttm)	387.00M -17.8%
Net Income	-632.00M
EPS	-13.19
Shares Out	54.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	705,300
Average Volume	827,265
Open	94.00
Previous Close	95.00
Day's Range	94.00 - 98.00
52-Week Range	87.00 - 181.00
Beta	-0.10
RSI	46.10
Earnings Date	May 12, 2026

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4576

Financial Performance

In 2025, TYO:4576's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.